Articles tagged with Fragile X Syndrome
Scientists have identified a new drug target for treating Fragile X syndrome by blocking the EPAC2 brain protein, which improves abnormal brain activity and behavioral symptoms. The study uses genetically engineered mice to simulate the condition and finds that EPAC2 levels rise gradually as the brain matures.
Researchers from the Salk Institute found that astrocytes play a crucial role in fragile X syndrome symptoms. Correcting dysregulations in star-shaped brain cells improved some symptoms, including reduced seizures and restored molecular balances in a mouse model of FXS. The study validates the importance of studying astrocytes in FXS r...
Researchers used base editing to correct the SCN8A gene mutation responsible for severe inherited epilepsy. The approach successfully eliminated or reduced seizures and improved brain function in lab mice, offering new hope for treating genetic epilepsies.
Researchers have discovered a novel biomarker for fragile X syndrome in both human patients and mouse models, allowing for the comparison of brain wave patterns between species. This breakthrough enables the development of more effective treatments by enabling non-invasive treatment efficacy readouts across species.
Researchers found that abundant mRNA molecules tend to cluster together in brain neurons, driven by chance overlap rather than coordinated movement. This discovery provides insights into how neurons manage genetic instructions and supports learning and memory, with potential implications for conditions like Fragile X syndrome.
Researchers at UC Davis MIND Institute recommend testing for specific groups, citing inadequate recognition by healthcare providers. The group of genetic conditions affects learning, development, and behavior, with millions of people unaware they carry the premutation.
Researchers have identified a previously unknown organelle called the hemifusome that plays a crucial role in cellular sorting and recycling. This discovery could lead to targeted treatments for complex genetic disorders like Hermansky-Pudlak syndrome, which affects multiple systems in the body.
Researchers found that bumetanide treatment normalizes neonatal social communication in newborn pups with the fragile X mutation, but reduces post-pubertal social interaction. The study suggests stage-specific effects on social development and raises questions about timing and dosing of bumetanide for targeted interventions.
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a severe condition affecting individuals with FMR1 gene mutations. A new study aims to understand which premutation carriers will develop FXTAS during middle or later adulthood and how it can be identified earlier.
The study analyzed the genetic profiles of 80,000 people and found that repeat expansion disorders (REDs) are common across different populations. The findings suggest a significant shift in how we think about genetic testing, profiling, and counseling for these conditions.
Research on mouse models reveals that CBD and metformin can alleviate repetitive behaviour, impaired speech, and learning impairments associated with these genetic conditions. The study also explores the potential for broader use of these treatments in autism spectrum disorder-related conditions.
Researchers found a bias in X-chromosome inactivation that protects females from harmful mutations linked to autism. The study suggests the paternal X chromosome is inactivated in 60% of cells, preventing mutation effects.
Researchers at UW-Madison discovered that FMRP regulates mitochondrial function in human brain cells even before birth, leading to a potential treatment for FXS. The study suggests that FMRP plays a critical role in prenatal development and may be linked to autism spectrum disorder.
Research finds that 75% of boys with fragile X meet criteria for co-occurring autism, but only 31% are identified in community settings. Early diagnosis is crucial to access services improving outcomes and quality of life.
Researchers are studying the characteristics of fragile X-associated tremor ataxia syndrome (FXTAS), aiming to develop treatments for this debilitating condition. The study focuses on understanding the phenotype of FXTAS, including its progression and impact on males and females.
Researchers boosted inhibitory interneuron activity in Fragile X mice, reducing hypersensitivity to sensory stimuli. The study found that even young mice with Fragile X had lower PV neuron density and functional decoupling, but treatment restored excitatory neuron function and reduced hypersensitivity.
A novel antisense therapy has restored fragile X protein production in human cell samples, revealing aberrant alternative splicing of messenger RNA as a key factor in fragile X syndrome. This finding offers real hope for developing new treatments and improving the lives of individuals affected by the condition.
A UC Riverside study identifies how a Fragile X gene mutation contributes to premature ovarian failure, leading to early infertility. Researchers found that the mutation affects neurons regulating reproduction in the brain and ovaries, causing an increase in hormone production and faster secretion rates.
Researchers found that the NIH Toolbox Cognition Battery is a promising option for measuring cognitive change in people with intellectual disability. The study shows that the test is sensitive to developmental changes in children, teens, and young adults, which can help guide effective interventions.
Researchers identified critical period plasticity in the amygdala that can be treated with therapeutic intervention at key developmental time points. Early pharmacological intervention was shown effective in reducing fear-learning in the mouse model.
Researchers identified a molecule produced by astrocytes that interferes with normal neuron development in Rett, fragile X and Down syndromes. Blocking this molecule reduces disease signs in mice brains, suggesting potential therapeutics to treat these disorders.
Researchers have discovered that inhibiting AKT, a key player in cell growth and survival, also decreases nonsense-mediated mRNA decay (NMD) in cells with fragile X syndrome. This finding provides new direction for developing treatments for the disorder and highlights the potential of existing drugs like Afuresertib.
The study found that the fragile X protein regulates the opening and closing of the GABA-A receptor in neurons from the brain's memory center, influencing how such neurons process information. This nuanced understanding may hold the key to developing effective therapies for fragile X syndrome.
A new study in mice identifies FXR1, a protein implicated in Fragile X syndrome, as a potential target for creating new blood pressure-lowering medicines. Deleting FXR1 in smooth muscle cells resulted in decreased diastolic blood pressure and altered vascular behavior.
A long-term study of FXTAS carriers has identified key indicators of disease progression, including cognitive decline and motor symptoms. Researchers hope to develop a validated tracking tool to monitor premutation carriers and patients with FXTAS.
A new DNA test has been developed to identify a range of hard-to-diagnose neurological and neuromuscular genetic diseases quicker and more accurately than existing tests. The test uses Nanopore sequencing technology to scan for abnormally long repeats within patients' genes, which are the hallmarks of disease.
A study by UC Riverside researchers shows that reactivating the Fmr1 gene in young transgenic mice with Fragile X syndrome eliminates symptoms. This breakthrough treatment offers hope for young children living with FXS and suggests targeting early brain development may be effective.
Researchers at Rutgers University have linked Fragile X and SHANK3 deletion syndrome, both associated with autism and health problems, to walking patterns. The study used motion-sensored sneakers to detect gait problems 15-20 years before clinical diagnosis, offering a potential framework for early intervention.
Researchers aim to understand language development in children with developmental language disorder (DLD) and Fragile X syndrome by examining grammar skills and executive functions. The study will gather data on a two-year developmental window, providing comprehensive insights for families and potential improvements in communication.
A new smartphone-based app, iBehavior, will be tested to improve the accuracy of data in clinical trials involving individuals with intellectual disability. The app uses ecological momentary assessment to track symptoms related to executive function, often associated with ADHD.
A new study in mice reveals that fragile X treatment can incur resistance, but also identifies potential strategies to overcome this. Administering mGluR5 inhibitors at a young age and then stopping may produce lasting benefits in cognitive ability.
A new study found that the economic burden of caring for children with rare genetic disorders such as Fragile X syndrome and Chromosome 15 imprinting disorders is significant. Earlier diagnosis and targeted interventions could reduce yearly costs by up to $734, depending on the child's intellectual functioning.
The article considers the ethical issues surrounding enrolling children with neurodevelopmental conditions, such as autism spectrum disorder and fragile X syndrome, in clinical trials. Parents may face difficult decisions about whether to enroll their children due to concerns about potential loss of positive aspects of their condition.
A phase two study found that an experimental treatment improved cognitive function and language in patients with fragile X syndrome. The treatment, BPN14770, increased levels of cyclic adenosine monophosphate (cAMP) in the brain, which is critically involved in memory formation.
Primary cilia, acting as cell TVs to detect signals, are present in fewer numbers in mice with Fragile X syndrome. Increasing their number might lead to reversing neurodevelopmental disorders like autism and intellectual disability.
Researchers discovered a range of co-existing conditions in patients with fragile X syndrome and premutation disorder. Lower FMRP levels are associated with emotional processing issues, including mood disorders, anxiety, and psychotic features. The study calls for more research on psychosis and FMRP levels, as well as greater awareness...
Researchers found that a telehealth-delivered behavioral intervention improved language skills in youth with fragile X syndrome, while lovastatin showed no efficacy. The study used Parent-Implemented Language Intervention (PILI) to enhance parent-child interactions and promote language development.
A new test measures expressive language skills in individuals with Fragile X syndrome, helping increase participation in clinical studies aimed at improving intellectual and cognitive functioning. The test's reliability and validity were demonstrated through consistent scores across multiple administrations.
A study by Michigan Medicine team discovered that repeat expansions cause neurodegenerative diseases but also found normal functions of these repeats in regulating protein production in healthy nerve cells. The research suggests a potential pathway for treating Fragile X syndrome and other disorders.
A study by Anglia Ruskin University found that sleep disturbance is common among young children with neurodevelopmental disorders, including Down's syndrome, Fragile X syndrome, and Williams syndrome. The research showed that improved sleep patterns were associated with better language skills in these children.
Researchers used a grip-force test to analyze sensorimotor function in people with the FMR1 premutation, identifying subtle symptoms and potential indicators of disease progression. The study aims to improve early diagnosis and treatment for Fragile X-associated tremor/ataxia syndrome (FXTAS) in at-risk individuals.
Research suggests that early lovastatin treatment in infancy can prevent learning problems in children with Fragile X Syndrome. The drug corrected memory and learning issues in rats with the genetic alteration, with benefits persisting for months after treatment ended.
A recent study by the University of Wisconsin-Madison reveals that mitochondrial dysfunction caused by a single mutation may be responsible for fragile X syndrome, autism, and other neural disorders. Researchers successfully reversed behavioral deficits in mice using a chemical treatment that restored mitochondria fusion.
A new study by Carnegie Institution researchers found that defects in the Fmr1 gene can lead to difficulties in creating large protein structures, potentially contributing to autism-related disorders like fragile X syndrome. The study used fruit fly eggs to demonstrate how Fmr1 helps produce essential large proteins.
Research shows that a pharmacological strategy can alleviate multiple behavioral and cellular deficiencies in a mouse model of fragile X syndrome. Treatment with GSK6A or a similar compound could be a viable strategy for addressing cognitive and behavioral problems in fragile X syndrome.
Scientists at Whitehead Institute have developed a modified CRISPR/Cas9 system to remove methylation tags from the FMR1 gene, restoring its expression and rescuing neurons from fragile X syndrome. This approach may prove useful for other diseases caused by abnormal methylation.
A study by Indiana University researchers found a link between the fragile X syndrome gene and excessive tissue growth. The discovery reveals a key biological mechanism behind the physical and mental impairments caused by fragile X syndrome, which affects 1 in 4,000 males and 1 in 6,000 females.
Researchers found an intervention that normalizes multiple biological functions in FXS mice by targeting protein synthesis and actin dynamics. The approach offers a potential treatment for Fragile X syndrome by regulating specific proteins involved in these processes.
A selective PDE4D inhibitor, BPN14770, has shown promise in treating Fragile X syndrome by reducing hyperarousal and improving social interactions. The treatment also exhibited long-term benefits, with no tolerance observed.
Researchers at Rockefeller University have discovered a potential new treatment for Fragile X Syndrome by targeting chromatin remodeling proteins, which play a key role in the disease's symptoms. The study found that inhibiting these proteins can alleviate symptoms and improve neuronal function.
A new study identifies the fragile X protein's role in regulating DNA packaging, offering clues for treatment. The protein oversees a set of genes that alter how DNA is packaged, and its absence leads to fragile X syndrome.
Fragile X syndrome is caused by a mutation in the Fragile X Mental Retardation 1 gene, leading to permanent changes in neural circuit structure and symptoms characteristic of ASD. Research confirms FMRP's essential role in refining brain processing during early development, highlighting the need for early detection and treatment methods.
A widely used diabetes medication, metformin, improves sociability and reduces symptomatic behaviors in adult mice with Fragile X syndrome. Researchers believe the drug could be repurposed as a therapy for this genetic disorder within a few years.
Research on fruit flies reveals that those lacking the Fragile X protein have less inhibition among their neurons, resulting in impaired information processing and increased anxiety. This finding provides valuable insights into human brain diseases and may lead to new treatments for Fragile X syndrome.
A Drexel University-led study found that Fragile X granules linger in the hippocampus of adult humans, expanding the age range for treatment. The study suggests that therapies targeting both dendrites and axons could be effective in treating symptoms of Fragile X syndrome and potentially other autism-related disorders.
A new study led by TSRI researchers discovered early brain changes in patients with Fragile X syndrome, a disorder affecting brain development. The study found that the mutation on the X chromosome triggers genome-wide DNA methylation changes, which may help explain similarities with autism spectrum disorder.
Researchers found that glial cells, including astrocytes, are impaired by the genetic defect and involved in symptoms of fragile X syndrome. The study suggests looking beyond neuronal effects to fully understand the disease.
A cancer drug has improved learning and memory in mice with fragile X syndrome by coaxes neural stem cells to generate neurons critical for cognitive function. The treatment targets the MDM2 enzyme, which is overactive in FMRP-deficient cells, leading to enhanced proliferation but reduced differentiation.
Researchers at VIB have identified a promising target pathway for treating fragile X syndrome and autism. By targeting the APP-ADAM10 pathway, scientists may be able to ameliorate deficits associated with these conditions. The study's findings open new avenues for developing non-toxic therapeutic agents.
A new study reveals that fragile X proteins FMRP and FXR2P play a vital role in the maturation of newly formed adult neurons. Mice lacking FXR2P had impaired learning and memory tasks, suggesting potential therapeutic targets for fragile X syndrome and autism. The study's findings also highlight the importance of fostering new nerve ce...